FACP

Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
Jeudi, mars 28, 2024
Washington Convention Center, Walter, FACG, FACP, AGAF, University, IGG, DDW, Gastroenterology, IBS, RFF

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC.
  • DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.
  • "We are excited that our technology will be prominently featured in a presentation at this year's DDW conference," said CEO Zack Irani.
  • "The forthcoming presentation marks a significant milestone, contributing valuable data to the growing clinical evidence supporting the efficacy of the InFoods IBS technology."

American Oncology Network Expands Footprint in Texas with the Addition of Woodlands Cancer Institute in Houston

Retrieved on: 
Mardi, mars 26, 2024
AON, MRCP, Oncology, Partnership, FACP, Radiation, Physician, Health, Nursing

WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks of independent oncology practices, is pleased to announce the opening of Woodlands Cancer Institute and welcomes its physicians to the network.

Key Points: 
  • WOODLANDS, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing networks of independent oncology practices, is pleased to announce the opening of Woodlands Cancer Institute and welcomes its physicians to the network.
  • Woodlands Cancer Institute is AON’s second practice in Texas and first in Montgomery County.
  • The practice specializes in delivering medical oncology, radiation oncology and hematology care and services in a community-based setting.
  • “On behalf of AON, I would like to extend a welcome to Woodlands Cancer Institute and their care team to our growing network of oncology practices,” said Anthony Belott , AON’s chief development officer.

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Retrieved on: 
Lundi, avril 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Colorectal cancer, Cetuximab, Progression-free survival, Patient, FACP, Bristol Myers Squibb, University, MD Anderson Cancer Center, AACR, Pacific Time Zone, CRC, FDA, PDUFA, Pharmaceutical industry

The data will also be published simultaneously in Cancer Discovery .

Key Points: 
  • The data will also be published simultaneously in Cancer Discovery .
  • The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually.
  • In previous studies, treatment with cetuximab as a single agent did not offer a clinical benefit in patients with KRAS-mutated colorectal cancer.
  • KRAZATI is a registered trademark of Mirati Therapeutics, Inc., a Bristol Myers Squibb company.

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
Mardi, avril 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Lundi, avril 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Vendredi, mars 22, 2024
Research, CKPT, FASN, Exercise, Biologics license application, Patent, Safety, Immunotherapy, Patient, FACP, Journal, CRL, Society, Nephrology, JITC, File, Marketing, FDA, Hematology, BLA, Alexion

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Key Points: 
  • WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.
  • We look forward to providing additional updates in the second quarter.”
    2023 and Recent Corporate Highlights:
    Checkpoint submitted a BLA to the FDA seeking approval of cosibelimab in January 2023 and the FDA accepted the BLA for filing in March 2023.
  • In December 2023, Checkpoint announced that the U.S. Patent and Trademark Office (“USPTO”) issued a new patent (U.S. Patent No.
  • In July 2023, Checkpoint announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cSCC.

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Retrieved on: 
Lundi, mars 18, 2024
Internal medicine, Circulatory system, Certification, CKPT, FASN, Biotechnology, FACP, Research, University, Nephrology, Society, Marketing, Hematology, Alexion, Bayer, Health, Hypertension, Pharmaceutical industry

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.

Key Points: 
  • WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.
  • Prior to joining Alexion, he served as Vice President of Medical Affairs for the Cardiovascular and Renal Division of Bayer Pharmaceuticals.
  • “We are pleased to welcome Dr. Sharma to our Board of Directors,” said James F. Oliviero, President and Chief Executive Officer of Checkpoint.
  • “He is a highly accomplished life sciences executive, with leadership experience in many facets of both patient care and the research, development, approval and commercialization of pharmaceutical products.

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Retrieved on: 
Jeudi, mars 14, 2024
Toxicity, Concept, Plasma, Candidate, RECIST, Oncology, RAS, Patient, FACP, City, Cancer, Pancreatic cancer, Neoplasm, Therapy, Safety, Pharmacokinetics, SLD, Pharmaceutical industry

“Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Key Points: 
  • “Today’s results are an important step towards that goal, as we share positive topline data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.
  • Immuneering evaluated both 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study.
  • The Phase 2a portion is expected to include up to twenty clinical sites and has already dosed its first patient.
  • Initial data from multiple arms of the Phase 2a portion of Immuneering’s Phase 1/2a study of IMM-1-104 expected in 2024.

IHA’s Symphony Chosen As Provider Directory Data Source for Covered California

Retrieved on: 
Jeudi, mars 14, 2024
Organization, IHA, FACP, PDM, Hospital, Policy, Affordable Care Act, California State Assembly, Senate, Directory, Health insurance

“Provider directory accuracy is critically important as new members come to Covered California and move between plans,” says Jeff Rideout, MD, MA, FACP, President and CEO of IHA.

Key Points: 
  • “Provider directory accuracy is critically important as new members come to Covered California and move between plans,” says Jeff Rideout, MD, MA, FACP, President and CEO of IHA.
  • All of the 12 Covered California Qualified Health Plans and provider networks are already actively engaged with Symphony.
  • Symphony currently identifies more than 80,000 corrections to provider directories every 30 days, ensuring health plans can maintain accurate provider directories.
  • Availity Provider Data Management (PDM), a web-based multi-player platform designed for provider information, supports Symphony’s data sharing, reconciliation, and validation for participating health plans, provider organizations, and small provider entities.

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Retrieved on: 
Vendredi, mars 15, 2024
Biotechnology, FDA, Pharmaceutical, Health, Emory University, Multiple myeloma, BMY, Development, Survival, ASH, Disease, Oncology, Patient, FACP, Committee, EMA, Cell therapy, Bristol Myers Squibb, MD, Winship Cancer Institute, European Medicines Agency, Society, ODAC, CHMP, Food, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.
  • The recommendation from the ODAC will be considered by the FDA during its ongoing review of the supplemental Biologics License Application (sBLA) for Abecma for this patient population.
  • The FDA has not yet assigned a new target action date for review of the sBLA.
  • “With patients becoming triple-class exposed earlier in the multiple myeloma treatment paradigm, it is critical that new treatment options with the potential to improve long-term outcomes are available as early as possible,” said Sagar Lonial, MD, FACP, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University.